Bionano Genomics (BNGO) Operating Expenses (2017 - 2026)

Bionano Genomics has disclosed Operating Expenses across 10 years of filings, most recently posting $11.1 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $11.1 million, down 2.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $46.3 million (down 43.45% YoY), and the FY2025 annual result was $46.5 million, down 55.42% from the prior year.
• Operating Expenses came in at $11.1 million for Q1 2026 at Bionano Genomics, down from $11.9 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $116.0 million in Q3 2023 to a low of $11.1 million in Q1 2026.
• The 5-year median for Operating Expenses is $30.8 million (2022), against an average of $30.9 million.
• Across the five-year window, Operating Expenses surged 241.48% in 2023 and tumbled 69.43% in 2024, its largest moves.
• Bionano Genomics' Operating Expenses stood at $39.3 million in 2022, then plunged by 30.36% to $27.4 million in 2023, then sank by 43.93% to $15.4 million in 2024, then dropped by 22.29% to $11.9 million in 2025, then decreased by 6.59% to $11.1 million in 2026.
• The last three Operating Expenses figures came in at $11.1 million (Q1 2026), $11.9 million (Q4 2025), and $11.9 million (Q3 2025), per Business Quant data.